# Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

> **NCT01454349** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sophiris Bio Corp** · enrollment: 40 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** PRX302
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01454349
- **Lead sponsor:** Sophiris Bio Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-03
- **Final completion:** 2013-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01454349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01454349, "Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01454349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*